What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections?

  • Esmaeil Mortaz Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands AND Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Milad Moloudizargari Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mohammad Varahram Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mehrnaz Movassaghi Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Johan Garssen Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands AND Nutricia Research Centre for Specialized Nutrition, Utrecht, The Netherlands
  • Mehdi Kazempour Dizagie Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Mehdi Mirsaeidi Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Miami, Coral Gables, Florida, USA
  • Ian M Adcock Cell and Molecular Biology Group, Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK
Keywords: Immunodeficiency, Interferon, Interleukin-12, Lung disease, Non-tuberculous mycobacteria


Nontuberculous mycobacteria (NTM) are categorized as one of the large and diverse groups of environmental organisms which are abundant in water and soil.  NTM cause a variety of diseases in humans that mainly affect the lung. A predisposition to pulmonary NTM is evident in patients with parenchymal structural diseases including bronchiectasis, emphysema, tuberculosis (TB), cystic fibrosis (CF), rheumatologic lung diseases and other chronic diseases with pulmonary manifestations. Lung infections are not the only consequences of being infected by NTM as they can also infect skin and soft tissue and may also cause lymphadenitis (predominantly in young children) and disseminated disease in human immunodeficiency virus (HIV)-infected patients or those with severely compromised immune system. NTM are also found in many subjects without any known risk factors.  Although the recent advances in imaging and microbiologic techniques including gene sequencing have provided a better view of the problems caused by NTM and has enhanced our understanding of the disease, many uncertainties regarding the immunologic response to NTM still exist. There is also limited data on the immunogenetics of NTM infection. Here, the authors reviewed the main immunogenetic defects as well as other immunological conditions which are associated with an increased the risk of NTM infections.


1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175(4):367-416.

2. Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, et al. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. Emerg Infect Dis 2017; 23(3):439-47.

3. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185(8):881-6.

4. Mirsaeidi M, Farshidpour M, Allen MB, Ebrahimi G, Falkinham JO. Highlight on advances in nontuberculous mycobacterial disease in North America. Biomed Res Int 2014; 2014:919474.

5. Lake MA, Ambrose LR, Lipman MC, Lowe DM. ‘” Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med 2016; 14(1):1.

6. Höflich C, Sabat R, Rosseau S, Temmesfeld B, Slevogt H, Döcke W-D, et al. Naturally occurring anti–IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004; 103(2):673-5.

7. Shima K, Sakagami T, Tanabe Y, Aoki N, Moro H, Koya T, Kagamu H, Hasegawa T, Suzuki E, Narita I. Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients. J Infect Chemother. 2014 Jan;20(1):52-6. 8. Patel SY, Ding L, Brown MR, Lantz L, Gay T, Cohen S, et al. Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005; 175(7):4769-76.

9. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129(2):341-8.

10. Nasiri MJ, Dabiri H, Darban-Sarokhalil D, Shahraki AH. Prevalence of non-tuberculosis mycobacterial infections among tuberculosis suspects in Iran: systematic review and meta-analysis. PloS one 2015; 10(6):e0129073.

11. Shahraki AH, Heidarieh P, Bostanabad SZ, Khosravi AD, Hashemzadeh M, Khandan S, et al. “Multidrug-resistant tuberculosis” may be nontuberculous mycobacteria. Eur J Intern Med 2015; 26(4):279-84.

12. Velayati AA, Farnia P, Mozafari M, Malekshahian D, Seif S, Rahideh S, et al. Molecular epidemiology of nontuberculous mycobacteria isolates from clinical and environmental sources of a metropolitan city. PloS one 2014; 9(12):e114428.

13. Sexton P, Harrison A. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008; 31(6):1322-33.

14. Wu U-I, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15(8):968-80.

15. Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, et al. Abnormal regulation of interferon-γ, interleukin-12, and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency. J Infect Dis 1998; 178(4):1095-104.

16. Jouanguy E, Dupuis S, Pallier A, Döffinger R, Fondanèche M-C, Fieschi C, et al. In a novel form of IFN-γ receptor 1 deficiency, cell surface receptors fail to bind IFN-γ. J Clin Invest 2000; 105(10):1429-36.

17. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A mutation in the interferon-γ–receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335(26):1941-9.

18. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998; 101(11):2364.

19. Chapgier A, Kong X-F, Boisson-Dupuis S, Jouanguy E, Averbuch D, Feinberg J, et al. A partial form of recessive STAT1 deficiency in humans. J Clin Invest 2009; 119(6):1502-14.

20. Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 2001; 293(5528):300-3.

21. Sampaio EP, Bax HI, Hsu AP, Kristosturyan E, Pechacek J, Chandrasekaran P, et al. A novel STAT1 mutation associated with disseminated mycobacterial disease. J Clin Immunol 2012;32(4):681-9.

22. Kreins AY, Ciancanelli MJ, Okada S, Kong X-F, Ramírez-Alejo N, Kilic SS, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015; 212(10):1641-62.

23. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365(2):127-38.

24. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science 2012; 337(6102):1684-8.

25. Filipe-Santos O, Bustamante J, Haverkamp MH, Vinolo E, Ku C-L, Puel A, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med 2006; 203(7):1745-59.

26. Nedorost ST, Elewski B, Tomford JW, Camisa C. Rosacea‐like lesions due to familial Mycobacterium avium‐intracellulare infection. Int J Dermatol 1991; 30(7):491-7.

27. Deffert C, Cachat J, Krause KH. Phagocyte NADPH oxidase, chronic granulomatous disease and mycobacterial infections. Cell Microbiol 2014; 16(8):1168-78.

28. Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, et al. The evolution of cellular deficiency in GATA2 mutation. Blood 2014; 123(6):863-74.

29. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014;123(6):809-21.

30. Collin M, Dickinson R, Bigley V. Haematopoietic and immune defects associated with GATA2 mutation. Br J Haematol 2015; 169(2):173-87.

31. Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118(10):2653-5.

32. Marciano BE, Huang C-Y, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol 2014; 133(4):1134-41.

33. Ahmad DS, Esmadi M, Steinmann WC. Idiopathic CD4Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases. Avicenna J Med 2013; 3(2):37.

34. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165(6):1082-5.

35. Mirsaeidi M, Vu A, Leitman P, Sharifi A, Wisliceny S, Leitman A, et al. A Patient-Based Analysis of the Geographic Distribution of Mycobacterium avium complex, Mycobacterium abscessus, and Mycobacterium kansasii Infections in the United States. Chest 2017; 151(4):947-50.

36. Ristola MA, von Reyn CF, Arbeit RD, Soini H, Lumio J, Ranki A, et al. High rates of disseminated infection due to non-tuberculous mycobacteria among AIDS patients in Finland. J Infect 1999; 39(1):61-7.

37. Amran FS, Kim K, Lim A, Thomson R, Lee S, Waterer G, et al. Is Pulmonary non-Tuberculous Mycobacterial Disease Linked with a High Burden of Latent Cytomegalovirus? J Clin Immunol 2016; 36(2):113-6.

38. Chen C-Y, Sheng W-H, Lai C-C, Liao C-H, Huang Y-T, Tsay W, et al. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis 2012; 31(6):1059-66.

39. Almyroudis N, Fabian J, Hahn T, Segal B, Wetzler M, McCarthy Jr P. Late infectious complications after cord blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2009; 28(11):1405-8.

40. Au W, Cheng V, Ho P, Yuen K, Hung I, Ma S, et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant 2003; 32(7):709-14.

41. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38(10):1428-39.

42. Weinstock D, Feinstein M, Sepkowitz K, Jakubowski A. High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31(11):1015-21.

43. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176(3):306-13.

44. Lai C-C, Tan C-K, Chou C-H, Hsu H-L, Liao C-H, Huang Y-T, et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000–2008. Emerg Infect Dis 2010; 16(2):294-6.

45. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 2007; 62(8):661-6.

46. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN, Boeree MJ, van Soolingen D. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011; 17(3):343-9.

47. Wallis R, Broder M, Wong J, Hanson M, Beenhouwer D. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38(9):1261-5.

48. Furst D, Breedveld F, Kalden J, Smolen J, Burmester G, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66(suppl 3):iii2-iii22.

49. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27(2):269-81.

50. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti–tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008; 59(8):1082-9.

51. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013; 17(11):e1000-4.

52. Hyrich K, Symmons D, Watson K, Silman A, Consortium BCC. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006; 65(7):895-8.

53. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent. N Engl J Med 2001; 345(15):1098-104.

54. Mohan AK, Timothy RC, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39(3):295-9.

55. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15(10):1556-61.

56. Van Ingen J, Boeree M, Janssen M, Ullmann E, De Lange W, De Haas P, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007; 3(7):414-9.

57. Maimon N, Brunton J, Chan AK, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007; 62(8):739-40.

58. Mori S, Sugimoto M. Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? Clin Rheumatol 2012; 31(2):203-10.

59. Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000; 11(4):321-33.

60. Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection. Blood 2012; 119(17):3933-9.

61. Kampmann B, Hemingway C, Stephens A, Davidson R, Goodsall A, Anderson S, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest 2005; 115(9):2480-8.

62. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 2014; 26(6):454-70.

63. Cottle L. Mendelian susceptibility to mycobacterial disease. Clin Genet 2011; 79(1):17-22.

64. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36(1):13-34.

65. Griffith DE, Girard WM, Wallace Jr RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993; 147(5):1271-8.

66. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178(10):1066-74.

67. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182(7):970-6.

68. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013; 17(11):e1000-e4.

69. Mirsaeidi M, Sadikot RT. Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. Int J Mycobacteriol 2015; 4(2):92-6.

70. Tsuyuguchi K, Suzuki K, Matsumoto H, Tanaka E, Amitani R, Kuze F. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol 2001; 123(3):428-34.

71. Danley J, Kwait R, Peterson DD, Sendecki J, Vaughn B, Nakisbendi K, et al. Normal estrogen, but low dehydroepiandrosterone levels, in women with pulmonaryMycobacteriumaviumcomplex.Apreliminary study. Ann Am Thorac Soc 2014; 11(6):908-14.

72. Jeon K, Kim SY, Jeong BH, Chang B, Shin SJ, Koh WJ. Severe vitamin D deficiency is associated with non‐tuberculous mycobacterial lung disease: A case‐control study. Respirology 2013; 18(6):983-8.

73. Chun RF, Adams JS, Hewison M. Immunomodulation by vitamin D: implications for TB. Expert Rev Clin Pharmacol 2011; 4(5):583-91.

74. Mirsaeidi M. Personalized medicine approach in mycobacterial disease. Int J Mycobacteriol 2012; 1(2):59-64.

75. Banoei MM, Mirsaeidi MS, Houshmand M, Tabarsi P, Ebrahimi G, Zargari L, et al. Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. Int J Infect Dis 2010; 14(1):e84-5.

76. Chen C, Liu Q, Zhu L, Yang H, Lu W. Vitamin D receptor gene polymorphisms on the risk of tuberculosis, a meta-analysis of 29 case-control studies. PLoS One 2013; 8(12):e83843.

77. Shahraki AH, Heidarieh P, Bostanabad SZ, Khosravi AD, Hashemzadeh M, Khandan S, et al. "Multidrug-resistant tuberculosis" may be nontuberculous mycobacteria. Eur J Intern Med 2015; 26(4):279-84.

78. Hojo M, Iikura M, Hirano S, Sugiyama H, Kobayashi N, Kudo K. Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long‐term inhaled corticosteroid therapy. Respirology 2012; 17(1):185-90.

79. Chu H, Zhao L, Xiao H, Zhang Z, Zhang J, Gui T, et al. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Arch Med Sci 2014; 10:661-8.

80. Andrejak C, Lescure F-X, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009; 64(4):291-6.

81. Andréjak C, Lescure F-X, Douadi Y, Laurans G, Smail A, Duhaut P, et al. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect 2007; 55(1):34-40.

82. Society RCotBT. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56(3):167-72.

83. Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68(3):256-62.

84. Lamb RC, Dawn G. Cutaneous non‐tuberculous mycobacterial infections. Int J Dermatol 2014; 53(10):1197-204.

85. Hypolite T, Grant-Kels JM, Chirch LM. Nontuberculous mycobacterial infections: a potential complication of cosmetic procedures. Int J Womens Dermatol 2015; 1(1):51-4.

86. Berliner JG, Aldabagh B, Mully T, Yu SS, Schwartz BS, Berger TG. Non-tuberculous mycobacterial infections following cosmetic laser procedures: a case report and review of the literature. J Drugs Dermatol 2015; 14(1):80-3.

87. Chan J-W, Trendell-Smith NJ, Chan J-Y, Hung I-N, Tang B-F, Cheng V-C, et al. Reactive and infective dermatoses associated with adult-onset immunodeficiency due to anti-interferon-gamma autoantibody: Sweet's syndrome and beyond. Dermatology 2013; 226(2):157-66.

88. Bi S, Hu F-S, Yu H-Y, Xu K-J, Zheng B-W, Ji Z-K, et al. Nontuberculous mycobacterial osteomyelitis. Infect Dis (Lond) 2015; 47(10):673-85.

89. John T, Velotta E. Nontuberculous (atypical) mycobacterial keratitis after LASIK: current status and clinical implications. Cornea 2005; 24(3):245-55.

90. Kheir WJ, Sheheitli H, Abdul Fattah M, Hamam RN. Nontuberculous mycobacterial ocular infections: a systematic review of the literature. Biomed Res Int 2015; 2015:164989.

How to Cite
Mortaz E, Moloudizargari M, Varahram M, Movassaghi M, Garssen J, Kazempour Dizagie M, Mirsaeidi M, Adcock I. What Immunological Defects Predispose to Non-tuberculosis Mycobacterial Infections?. Iran J Allergy Asthma Immunol. 17(2):100-109.
Review Article(s)